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Abstract
5-HT
1A
 receptor is one of the most important members of the numerous families of sero-
toninergic receptors. Though it was the first 5-HT receptor to be identified and cloned, 
the knowledge of its activation/transduction mechanisms, mediated effects, and connec-
tion with other systems is still uncompleted. For this reason, relevant is the study of the 
four Ws of the title: first of all “who” this receptor is, then “why” it continues to be a so 
attractive target after several years after its identification, then “where” is 5-HT
1A
 recep-
tor expressed within the body, and, finally, “what” effects this receptor can elicit under 
physiological and pathological conditions. Obviously, more and more potent, safe, and 
selective “drugs” might be discovered once the responses to these questions are given.
Keywords: 5-HT
1A
 receptor, 5-HT
1A
 transduction mechanisms, central nervous system 
diseases, 5-HT
1A
 ligands, structure-activity relationship studies
1. Introduction
The rational research of novel efficacious and safe drugs is mainly based on the knowledge of 
biological systems, whose dysfunctions cause several pathological conditions. Receptors and 
enzymes are the most common targets to which the so-called charmed bullets by Paul Ehrlich 
(1854–1915), Nobel Prize in Physiology and Medicine in 1908, should be addressed to mean 
the selectivity of interaction and, therefore, the reduced occurrence of unwanted side effects. 
Serotonin receptors (5-HTRs) are the most widespread targets of drugs because of the numerous 
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biological effects of the endogenous ligand serotonin (5-HT; Figure 1) and the wide presence of 
different 5-HTR subtypes in both the central and peripheral nervous systems (CNS and PNS) [1].
5-HT is biosynthesized at the periphery into the gut by intestinal enterochromaffin cells and 
in the CNS in the raphe nucleus from the essential amino acid L-tryptophan. A 5-HT reuptake 
protein (SERT) is responsible for carrying the neurotransmitter from the synaptic cleft to its 
target nerve and acts as a regulator of 5-HT levels. In the CNS, SERT is a key target for vari-
ous antidepressant drugs such as tricyclic antidepressants (TCAs), selective serotonin reup-
take inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). 5-HT is 
mainly deaminated by monoamine oxidase A (MAO A) to the corresponding aldehyde in the 
liver. The physiological effects of 5-HT are mediated by several 5-HTRs, whose heterogene-
ity was hypothesized from pharmacological characterization in the 1950s. From radioligand 
experiments, the first evidences of 5-HT subtypes were reported in 1979 [2]. To date molecu-
lar cloning techniques, amino acid sequence determination, evaluation of its pharmacologi-
cal properties, second messenger coupling, and signal transduction characterization have 
allowed the identification of at least seven subfamilies (5-HT1–7), some of which are further subdivided into different subtypes (Figure 2).
Figure 2. Classification of 5-HT
1A
Rs.
Figure 1. Chemical structure of 5-HT.
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While 5-HT
3
Rs are cation-permeable ion channels, all the others are G-protein-coupled recep-
tors (GPCRs) and are classified as rhodopsine-like receptors (class A). Among the 5-HTRs, 
the 5-HT
1A
 subtype was the first to be cloned [3] and pharmacologically characterized, and 
it is one of the most studied. For this reason, it is often ironically called “old target” [4]. The 
human 5-HT
1A
R consists of 422 amino acid residues with a molecular weight of about 46,000 
Da. Though its structure is still unknown, mutagenesis studies have allowed the identification 
of amino acid residues responsible for ligand binding and G-protein coupling [1].
2. Localization
5-HT
1A
Rs are widely expressed in the brain of mammals, including humans [5]. The main 
expressions are in limbic areas, such as the hippocampus, lateral septum, cortical brain 
regions, as well as dorsal and medial raphe nuclei (DRN and MRN) (Figure 3).
5-HT
1A
Rs are located within the brain both pre- and postsynaptically. Presynaptic 5-HT
1A
Rs 
are expressed in all 5-HT neurons (autoreceptors) and in a lot of non-5-HT neurons (hetero-
receptors). The latter modulate the release of several neurotransmitters, including glutamate 
and dopamine, and hormones (adrenocorticotropin (ACHT), oxytocin, prolactin, growth hor-
mone, β-endorphin). In the brainstem, presynaptic autoreceptors are expressed in serotoner-
gic neurons in DRN and MRN, where their activation inhibits cell firing rate. These neurons 
send ascending 5-HT fibers to the forebrain attenuating 5-HT synthesis, turnover, and release 
in projection areas from axon terminals, working on a basis of a negative feedback. Presynaptic 
Figure 3. Central localization of 5-HT
1A
Rs (Adapted from CNSforum image bank, Lundbeck Institute “Distribution of 
5-HT
1A
 receptors” http://www.cnsforum.com/imagebank/item/hrl_Rcpt_sys_SN1A_dist/default.aspx).
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5-HT
1A
Rs expressed in DRN, through coupling to Gαi/o proteins, decrease rate of cell firing by the activation of inwardly rectifying potassium channels. Postsynaptic 5-HT
1A
Rs are found at 
high density in limbic regions, such as the hippocampus and septum, and in the frontal and 
entorhinal cortices. Lower 5-HT
1A
R levels are observed in the amygdala. As in the case of pre-
synaptic receptors, the activation of postsynaptic 5-HT
1A
Rs generally decreases the firing rate 
of postsynaptic cells. Electrophysiological, pharmacological, and biochemical evidences have 
demonstrated that 5-HT
1A
Rs are localized in primary afferent neurons [4]. They are also present 
in the gut, in the enteric nervous system, as well as in smooth muscle, where their activation 
inhibits relaxation or contraction.
3. Signal transduction pathways of 5-HT
1A
Rs
The primary transduction pathway of 5-HT
1A
Rs is the inhibition of adenylate cyclase (AC). 
Nevertheless, various other pathways are coupled to this receptor depending on the tar-
get cell. Indeed, 5-HT
1A
R stimulation activates or inhibits different enzymes, channels, and 
kinases, as well as modulates the production of several second messengers (Figure 4) [6, 7].
Whatever is the activated second messenger, the signals initiated by the stimulation of 
5-HT
1A
Rs implicate the involvement of Gi/o protein. Moreover, a G-protein-independent path-
way of 5-HT
1A
R coupling to a smooth inward current has also been suggested.
3.1. AC inhibition
The activation of 5-HT
1A
Rs inhibits AC and reduces the production of cAMP with a conse-
quent decrease of protein kinase A (PKA) activity. The Gα
i
-induced inhibition of AC is cou-
pled to 5-HT
1A
 heteroreceptors, whereas the situation is still unclear for 5-HT
1A
 autoreceptors. 
Indeed, some results reveal that 5-HT
1A
R partial agonists negatively regulate presynaptic AC 
activity in raphe nuclei. On the other hand, a lot of evidences highlight that 5-HT
1A
R agonists 
do not inhibit forskolin-stimulated AC activity in homogenates of the raphe region, suggest-
ing that these autoreceptors do not couple to AC. 5-HT
1A
R agonists also reduce PKA activ-
ity in the hippocampus, determining increased protein phosphatase-1 activity and reduction 
of Calcium/calmodulin-dependent protein kinase II phosphorylation. This signaling effect is 
joined to cognitive deficits. Therefore, cognitive behaviors can be mediated by the inhibition 
of AC/PKA activity induced by 5-HT
1A
Rs.
3.2. GIRK and Ca2+ channel opening
Through coupling to Gαi/o proteins, 5-HT1ARs activate inwardly rectifying potassium channels (GIRKs) in the hippocampus and DRN. Such an action hyperpolarizes neurons and decreases firing. Moreover, 
Ca2+ entry is reduced by the inhibition of voltage-gated Ca2+ channel following 5-HT
1A
R activation.
3.3. ERK/MAPK pathway activation
The stimulation of 5-HT
1A
Rs induces the release of βγ-complex that participates in the activation 
of phosphatidylinositol-3 kinase (PI3K). It triggers the activation of extracellular signal-regulated 
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protein kinase (ERK) (or MAPK), implicated in cell proliferation and differentiation through 
two pathways involving Ras-Raf-MEK proteins. In addition, 5-HT
1A
-induced ERK activation in 
nonneuronal cells can be mediated by phosphatidylcholine-specific phospholipase C (PC-PLC) 
in a G-protein-dependent manner. In neuronal cells, the effects on ERK activity produced by 
5-HT
1A
Rs can be different. Indeed, in the hypothalamus a rapid but transient increase of ERK 
phosphorylation is observed, and this effect might be an intermediate step for the 5-HT
1A
R-
mediated increase of oxytocin, ACTH, and prolactin. In HN2-5 hippocampal-derived cell lines, 
5-HT
1A
R activation favors ERK phosphorylation and activity. This effect does not occur in the 
primary culture of hippocampal or fetal rhombencephalic neurons. On the contrary, in the rat 
hippocampus, 5-HT
1A
R activation decreases ERK phosphorylation. Analogously it reduces MEK 
activity and ERK phosphorylation in differentiated raphe neurons. Different ERK-related effec-
tors can be modulated by 5-HT
1A
Rs: activation of the ribosomal S6 kinase (RSK), stimulation of 
Figure 4. Main transduction pathways of 5-HT
1A
Rs (Reprinted with permission from Ref. [6]).
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nuclear factor κB (NF-κB), and inhibition of caspase 3. This pathway seems to be involved in 
neuroprotective mechanisms. ERK also activates cAMP response element binding (CREB), a 
transcription factor that plays fundamental roles in stress, anxiety, and depression. Finally, the 
activation of MAPK/ERK transduction pathway may inhibit apoptosis by phosphorylation of 
the proapoptotic protein Bad and by increasing the expression of antiapoptotic Bcl-2.
3.4. PI3K and Akt pathway activation
5-HT
1A
R stimulation can also regulate the activation of the PI3K/Akt signaling pathway 
through βγ-complex. The Akt protein kinase plays a key role in several cellular processes, 
such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. 
In the mammalian brain, the PI3K/Akt pathway is also implicated in synaptic plasticity, 
learning, and memory. Consequently, Akt dysfunction can be associated with metabolic dis-
eases (e.g., diabetes and obesity), central disorders (e.g., depression, schizophrenia, and drug 
abuse), and the most frequent alterations observed in human cancer and tumor cells. Akt 
phosphorylates and inactivates the protein glycogen synthase kinase 3 (GSK3), whose inhi-
bition produces antidepressant and antimanic effects. Active Akt also phosphorylates and 
inactivates Forkhead box O (FoxO) transcription factors, whose deficiency in mice develops 
antidepressive and anxiolytic behavioral phenotypes.
3.5. Na+/H+ exchanger activation
Another complex pathway following 5-HT
1A
R stimulation and involving G(i2)α and/or 
G(i3)α induces Janus kinase 2 (Jak2) activation, which leads to tyrosine phosphorylation of 
calmodulin (CaM). The consequent increase of CaM binding to Na+/H+ exchangers (NHEs) 
induces a conformational modification that activates NHEs, unmasking an obscured proton-
sensing and/or proton-transporting region. NHEs, expressed on the surface of all mammalian 
cells, regulate cell volume, intracellular pH, and transepithelial transport of Na+ and acid-base 
equivalents.
3.6. NO production
5-HT
1A
Rs can also regulate the production of nitric oxide (NO) that plays an important role 
in the brain. In rat ventral prostate cells, 5-HT
1A
Rs can stimulate NO synthase (NOS) activity, 
whereas in the adult rat hippocampus and in human neocortical slices, they inhibit NMDA-
induced NO production. Therefore, the regulation of NO synthesis by 5-HT
1A
Rs is complex 
and appears to be cell specific.
4. Biological interest of 5-HT
1A
Rs
5-HT
1A
R is one of the most important among the 5-HTRs because of its high affinity for 5-HT 
and involvement in nearly all 5-HT-mediated effects. The main behavioral and physiological 
functions mediated by this receptor are summarized in Figure 5.
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4.1. Depression
The dysfunction of 5-HT
1A
 autoreceptors has been proven to be associated with the major 
depressive disorders. This correlation is confirmed by the observation that significant antide-
pressant activity is elicited by 5-HT
1A
R agonists [4]. Though the mechanism responsible for 
their antidepressant action is still unclear, desensitization or downregulation of presynaptic 
5-HT
1A
Rs appears to be implicated in this pharmacological effect. Indeed, in DRN and MRN, 
prolonged treatment with 5-HT
1A
R agonists desensitizes presynaptic 5-HT
1A
Rs inducing a 
reduction of autoreceptor-mediated inhibition of 5-HT release.
SSRIs represent the first-line treatment of depression. However, the inhibition of the reuptake 
of 5-HT increases 5-HT concentration in the synaptic cleft and simultaneously activates 5-HT
1A
 
autoreceptors, with a consequent suppression of 5-HT release from presynaptic terminals [8]. 
Therefore, only prolonged treatment with SSRIs allows the desensitization of 5-HT
1A
 autore-
ceptors, leading to the recovery of neurotransmission in 5-HT neurons. Beneficial effects on 
depression are also produced by the combination of SSRIs with 5-HT
1A
R agonists or antag-
onists, leading to faster onset of antidepressant action and greater antidepressant efficacy. 
Figure 5. Main behavioral and physiological functions mediated by 5-HT
1A
Rs.
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In particular, 5-HT
1A
R antagonists can improve the efficacy of SSRIs by blocking inhibitory 
5-HT
1A
 autoreceptors, while 5-HT
1A
R agonists exert antidepressant-like effect through the acti-
vation of postsynaptic 5-HT
1A
Rs and/or faster desensitization of 5-HT
1A
 autoreceptors. Finally, 
antidepressant-like effect can also be produced by 5-HT
1A
 partial agonism combined with 
5-HT reuptake inhibition [4].
4.2. Anxiety
Several studies have been performed to demonstrate the possible role of 5-HT
1A
Rs in anxi-
ety [1]. Interestingly, mice with genetically inactivated 5-HT
1A
R gene develop an anxiety-like 
phenotype, probably resulting from impaired autoinhibitory control of midbrain 5-HT neu-
rons. On the contrary, mice with overexpressed 5-HT
1A
Rs display diminished anxiety when 
compared to wild-type animals. These findings support the crucial role of the stimulation of 
5-HT
1A
Rs in the control of anxiety-like behavior. Therefore, 5-HT
1A
R agonists and partial ago-
nists have been developed as novel anxiolytic agents, devoid of dependence and side effect 
profile of other anxiolytics and antipsychotics.
4.3. Schizophrenia
Several studies performed in postmortem schizophrenia patients report an overexpression of 
5-HT
1A
Rs in the prefrontal cortex, indicating that these receptors are not adequately stimu-
lated by 5-HT [1]. Therefore, 5-HT
1A
R agonists might be useful to contrast this apparent defi-
cit. Two mechanisms are advantageously activated by 5-HT
1A
R stimulation in the treatment 
of schizophrenia. The first one involves the attenuation of parkinsonian symptoms, such as 
catalepsy, caused by the antagonism at dopamine D
2
 receptor (D
2
R) produced by antipsychot-
ics. Since atypical antipsychotic drugs, such as clozapine, quetiapine, and ziprasidone, also 
behave as potent 5-HT
1A
R agonists, it has been suggested that the reduced incidence of motor 
side effects observed with these drugs might be due to their inherent 5-HT
1A
R agonism. The 
second mechanism involves the ability of 5-HT
1A
R agonists to increase dopamine release in 
the prefrontal cortex, consequently reducing the negative symptoms of schizophrenia. Based 
on these observations, a novel approach in the treatment of schizophrenia concerns the devel-
opment of novel atypical antipsychotic agents characterized by a mixed D
2
R antagonist/5-
HT
1A
R agonist profile.
4.4. Pain
Full and partial 5-HT
1A
R agonists are beneficial in pain treatments, including efficacy in neu-
ropathic pain models, arousing great interest as future therapeutic agents. In knockout mice, 
5-HT
1A
Rs have also been demonstrated to mediate an endogenous inhibitory control of noci-
ception evoked by thermal noxious stimuli [4].
4.5. Drug addiction
A critical role in the effects of psychostimulants, including addiction, is played by 
5-HT
1A
Rs. Some psychostimulant drugs, including cocaine, amphetamine, methamphetamine, 
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and 3,4-methylenedioxymethamphetamine (MDMA), increase not only dopamine but also 
5-HT that can hyperactivate 5-HT
1A
Rs. Interestingly, the contribution of pre- and postsynaptic 
5-HT
1A
Rs can be dissociated and frequently is responsible for opposite effects. In fact, 5-HT
1A
 
autoreceptors indirectly facilitate psychostimulant addiction-related behaviors by reducing 
5-HT response in projection terminal areas, while postsynaptic 5-HT
1A
Rs directly contrast the 
expression of various addiction-related behaviors [9]. Several studies have also demonstrated 
that 5-HT
1A
R agonists alleviate opioid-induced respiratory depression in rodent models. The 
mechanisms involved in this effect are still unclear. However, concomitant decreases in opioid-
induced analgesia, as well as altered baseline ventilation and behavior, have also been observed.
4.6. Dyskinesia
5-HT
1A
Rs are involved in the regulation of locomotor activity. In particular, the stimulation of 
5-HT
1A
Rs facilitates the establishment of locomotor sensitization [10]. Parkinsonian patients 
in therapy with L-3,4-dihydroxyphenylalanine (L-DOPA) may develop motor complications, 
such as dyskinesia. The development of this side effect involves several pathways, including 
an abnormal 5-HT-mediated neurotransmission [4]. It has been highlighted that parkinsonian 
animals chronically treated with L-DOPA have increased levels of 5-HT
1A
Rs in the striatal 
matrix. Accordingly, treatment with 5-HT
1A
R agonists attenuates dyskinesia but, in some 
cases, also reduces the antiparkinsonian benefit of L-DOPA. Some evidences suggest that a 
lot of 5-HT
1A
R agonists are also endowed with D
2
R antagonism, which alleviates dyskinesia, 
though at the expense of worsening parkinsonism. The challenge is to obtain compounds able 
to selectively stimulate 5-HT
1A
Rs in striatus and/or in middle layers of the cortex, avoiding the 
involvement of 5-HT
1A
Rs in external cortical layers.
4.7. Neuroprotection
The activation of 5-HT
1A
Rs exerts a neuroprotective effect in different animal models of isch-
emia, interfering with excitotoxic and apoptotic cell death processes in the postischemic brain 
[1]. Though the cellular mechanisms underlying such a neuroprotective effect are still unclear, 
the hyperpolarization of pyramidal neurons inhibits the glutamate-induced excitotoxicity 
consequent to cerebral ischemia. 5-HT
1A
Rs may mediate brain protective mechanisms, by 
contrasting the effects of glutamatergic NMDA receptor overstimulation and the consequent 
NMDA-induced Ca2+ influx. Moreover, the inhibition of 5-HT
1A
R-induced cyclases might pro-
duce neuroprotective effects due to the reduction of adenylyl cyclase excess following reper-
fusion after ischemic attack. 5-HT
1A
R agonists can also be useful for the treatment of traumatic 
brain injury (TBI) [11].
4.8. Memory
Several experimental evidences highlight that the activation of postsynaptic 5-HT
1A
Rs, 
attenuating the neuronal activity, impairs emotional memory. On the contrary, presyn-
aptic 5-HT
1A
R activation reduces 5-HT release and exerts pro-cognitive effects. 5-HT
1A
R 
antagonism facilitates memory retention, probably by the activation of 5-HT7Rs, and evi-dence is provided that 5-HT7Rs can facilitate emotional memory upon reduced 5-HT1AR 
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transmission [12]. Moreover, tonic and phasic 5-HT release can exert different and poten-
tially opposite effects on emotional memory, depending on the states of 5-HT
1A
Rs and 
5-HT7Rs and their interaction. Consequently, individual differences due to genetic and/or epigenetic mechanisms play an essential role in the responsiveness to drug treatment [13].
4.9. Sexual function
5-HT
1A
Rs and 5-HT2CRs produce two distinct and opposite effects on sexual function: the activation of 5-HT
1A
Rs decreases ejaculatory latency and erection, directly promoting the 
sympathetic emission, while the activation of 5-HT2CRs increases them, directly favoring parasympathetic expulsion and erection [4]. Therefore, 5-HT
1A
R antagonists are under inves-
tigation for the treatment of primary premature ejaculation.
4.10. Cardiovascular system
Several studies have demonstrated that 5-HT
1A
Rs in the medullary raphe mediate protective 
responses to stress [4]. Indeed, the activation of 5-HT
1A
Rs induces bradycardia and blood 
pressure decrease, suggesting that 5-HT
1A
Rs can reduce the sympathetic outflow. Moreover, 
5-HT
1A
R agonists reduce the cutaneous vasoconstriction evoked by physical and psycho-
logical stressors. 5-HT
1A
Rs located in limbic regions can also reduce stress-evoked cardio-
vascular responses. However, this action does not occur via a direct effect on brainstem 
cardiovascular neurons, but is consequent to the anxiolytic effect. Psychological stress, cold 
exposure, or fever might elicit cardiovascular responses also mediated by neurons within the 
dorsomedial hypothalamus. Therefore, 5-HT
1A
R agonists might be useful therapeutic agents 
to reduce the sympathetic responses occurring in some forms of hypertension and heart 
failure. The cardiovascular responses of 5-HT
1A
R agonists could also be useful to reduce side 
effects in the treatment of hyperphagia and obesity with noradrenaline (NA) uptake inhibi-
tors. Such inhibitors are able to reduce food intake due to increased noradrenergic activity 
that also causes an increased cardiovascular activity. When 5-HT
1A
R agonists are combined 
with NA uptake inhibitors, side effects, such as hypertension and tachycardia, are mitigated. 
Postsynaptic 5-HT
1A
R activation may contribute to hypophagia efficacy. Moreover, presyn-
aptic 5-HT
1A
Rs may reduce food intake by inhibiting spontaneous noradrenergic cell firing.
4.11. Urogenital system
5-HT
1A
Rs mediate effects in the lower urinary tract function [4]. Indeed, their stimulation acti-
vates the micturition reflex, inducing an increase in the frequency of isovolumic bladder con-
tractions. Conversely, 5-HT
1A
R agonists elicit periodic external urethral sphincter relaxation, 
inducing an increase in micturition volume, a decrease in bladder capacity, and an increase 
in voiding efficiency.
4.12. Pupillary dilation
Pupillary response to 5-HT
1A
R agonists is species dependent [14]. Indeed, 5-HT
1A
R activation 
produces miosis in humans and rabbits and mydriasis in mice. In humans, 5-HT
1A
Rs induce 
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miosis solely by inhibiting sympathetic mechanisms. However, evidences suggest that the 
parasympathetic nerve is also involved. Indeed, the activation of central 5-HT
1A
Rs induces NA 
release, which in turn reduces parasympathetic neuronal tone to the iris sphincter muscle by the 
stimulation of postsynaptic α
2
-adrenoceptors (α
2
-ARs) within the Edinger-Westphal nucleus.
4.13. Cancer
5-HT
1A
Rs are known to be involved in the proliferation of human tumor cells, but their func-
tion still remains poorly understood [4]. 5-HT
1A
R antagonists inhibit the growth of different 
prostatic tumor cell lines, such as PC-3, DU-145, and LNCaP, as well as the proliferation of 
PC-3 xenografted subcutaneously in athymic nude mice. Multitarget ligands, acting as α
1A
/
α
1D
-AR and 5-HT
1A
R antagonists, in which a synergic effect occurs, have proved to be useful 
in the management of benign prostatic hyperplasia. 5-HT
1A
Rs are also reported to be involved 
in the mitogenic effect of 5-HT in human small cell lung carcinoma cells.
5. Ligands
Several structurally different ligands, such as aryloxyalkylamines, arylpiperazines, amino-
tetralins, indolyl-alkylamines, ergolines, and aporphines, are known to bind 5-HT
1A
Rs [15]. 
Recently, new classes of ligands, including 2-imidazoline and 1,4-dioxane derivatives, have 
also shown high 5-HT
1A
R affinity. Due to the high homology among 5-HT
1A
Rs and other recep-
tor systems, in binding studies several molecules show nanomolar and subnanomolar affinity 
not only for 5-HT
1A
Rs but also for other receptors (5-HT
2A
Rs, 5-HT2CRs, 5-HT7Rs, α1- and α 2-ARs, as well as D
1
Rs and D
2
Rs).
5.1. Aryloxyalkylamines
The sequence analysis of the 5-HT
1A
R genomic clone indicates 43% amino acid homology 
with the β
2
-AR in the transmembrane domain. Therefore, some compounds show good affin-
ity for both systems. The first examples of dualistic interaction are offered by pindolol (1) and 
propranolol (2) (Figure 6) [16].
In several studies, an Asn amino acid residue in the putative helix VII of 5-HT
1A
Rs has been 
demonstrated to play a crucial role in the binding of aryloxypropanolamines. Indeed, for 
example, propranolol 2 shows significantly reduced affinity for human 5-HT
1A
Rs, in which 
Figure 6. Chemical structures of 1–3.
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the Asn386 is replaced by valine, while the affinity of the neurotransmitter 5-HT is hardly 
affected. It was initially hypothesized that the formation of two hydrogen bonds occurs 
between the oxypropanol moiety and the amide group of Asn386. Moreover, since the (S)-
enantiomer of propranolol is 13-fold more potent than the (R)-enantiomer at wild type (pK
i
 
5-HT
1A
R = 6.8 and 5.7, respectively) and the enantioselectivity is significantly reduced (three-
fold) in Asn386Val mutant human 5-HT
1A
Rs (pK
i
 5-HT
1A
R = 5.4 and 5.0, respectively), Asn386 
proves to behave as a chiral discriminator. Moreover, the observation that the replacement of 
the hydroxyl substituent of 2 with a methoxy group does not affect the high affinity for the 
wild-type receptor suggests that one or both ether oxygen atoms of (S)-3 may act as hydrogen 
bond acceptors. (S)-3 (pK
i
 5-HT
1A
R = 6.8) also shows high affinity for the Asn386Val mutant 
receptor because of a favorable lipophilic contact of its methoxy group with Val386.
5.2. Arylpiperazines
Arylpiperazines are one of the most important classes of 5-HT
1A
R ligands from which a second 
generation of anxiolytics, including buspirone (4), the antipsychotics ziprasidone (5), perospi-
rone (6), and aripiprazole (7), and several pharmacological tools originated (Figure 7) [8].
These ligands bind with high affinity to different GPCRs; the two multitarget drugs 5 and 
6, for example, acting as D
2
R antagonists and 5-HT
1A
R agonists, were marketed in 2001 
and 2002, respectively, for the management of schizophrenia [4]. Compound 4 is the most 
known member of long-chain arylpiperazines (LCPAs) [17]. It was initially investigated 
as a putative antipsychotic agent devoid of the typical side effects of this class of drugs 
but was launched in the market as an anxiolytic in the USA in the 1980s. It behaves as a 
Figure 7. Chemical structures of 4–8.
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potent but nonselective partial 5-HT
1A
R agonist and D
2
R antagonist. Since its launch, several 
N4-(2-pyrimidinyl)piperazines containing an N1-imidobutyl substituent have originated 
as the third generation of anxiolytic agents, including the partial agonist tandospirone (8) 
(Figure 7).
The general structure of arylpiperazines consists of a terminal fragment containing an amide, 
imide, alkyl, arylalkyl, heteroarylalkyl, or tetralin function linked through a flexible aliphatic 
chain of variable length to the N1-arylpiperazine moiety [8]. The search for new derivatives 
has been focused on the modification of one or more portions of such a pharmacophore. Some 
of the main changes are schematically reported in Figure 8.
5.2.1. Modification of the aryl group
The replacement of the 2-pyrimidinyl moiety of 4 with a 2-methoxyphenyl group leads to the 
antidepressant BMY 8227 (9), from which BMY 7378 (10) originates by shortening its butyl 
Figure 8. Pharmacophore of arylpiperazines.
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to ethyl chain (Figure 9) [15]. Compounds 9 and 10 belong to a generation of postsynaptic 
5-HT
1A
R antagonists, which also behave as low efficacy partial agonists [4].
The 2-methoxyphenyl group is also present in the WAY series, including WAY 100135 (11) 
and WAY 100635 (12) (Figure 9). These compounds, also called “silent” 5-HT
1A
R antagonists, 
behave as antagonists at both pre- and postsynaptic 5-HT
1A
Rs. In the case of 11, the (S)-
enantiomer is 28-fold more potent than its (R)-antipode.
The incorporation of the o-methoxy group into an annulated benzodioxane or benzofurane 
ring, affording two series of heterobicyclic arylpiperazines, is consistent with the mainte-
nance of high 5-HT
1A
R affinity [15]. The benzodioxane fragment is present in the structure of 
flesinoxan (13) (Figure 10), a potent agonist at both pre- and postsynaptic 5-HT
1A
Rs [15]. An 
example of benzofuran derivative showing high 5-HT
1A
R affinity is compound 14 (Figure 10).
Moderate to high affinity for 5-HT
1A
Rs and SERT and low affinity for 5-HT
2A
R are recorded by 
ligands, whose four-carbon chain bears a quinoline moiety (Figure 11) [8].
Figure 10. Chemical structures of 13–14.
Figure 11. General structure of quinoline derivatives.
Figure 9. Chemical structures of 9–12.
Serotonin - A Chemical Messenger Between All Types of Living Cells80
5.2.2. Modification of the piperazine ring
N1-Arylpiperazine moiety plays an important role in the affinity for 5-HT
1A
Rs. This template 
has been duplicated to successfully obtain selective homo- and heterobivalent ligands [18]. 
Indeed, compound 15 shows high affinity for 5-HT
1A
Rs and selectivity over 5-HT7Rs, whereas compound 16 selectively targets 5-HT7Rs (pKi = 7.4) (Figure 12).
The piperazine ring can be replaced by a piperidine one. The most representative example 
is befiradol (17), a very potent and highly selective 5-HT
1A
R full agonist (Figure 13), that 
also shows efficacy in a rodent model of neuropathic, inflammatory, and surgical pain. It 
is endowed with potent analgesic and antiallodynic effects that are comparable to those of 
high doses of opioids. However, lower and fewer side effects are triggered, and little or no 
development of tolerance is manifested by 17. In 2013, 17 was marketed by Neurolixis with 
indication for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease [19]. The 
3-chloro-4-fluorophenyl moiety of 17 can be bioisosterically replaced by both unsaturated 
and saturated lipophilic moieties [20]. Among the investigated compounds, the highly selec-
tive 5-HT
1A
R superagonist benzothiophene-3-carboxamide 18 almost exclusively recognizes 
5-HT
1A
Rs (Figure 13).
A series of 2H-pyrido[1,2-c]pyrimidine derivatives, bearing a piperidinyl-indole residue in 
their pharmacophore (Figure 13), shows very high-affinity values for both 5-HT
1A
Rs and 
SERTs. Compound 19 is a representative example [21]. The presence of a tetrahydropyridinyl-
indole moiety reduces binding to 5-HT
1A
Rs, while a Cl substituent in R
3
 reduces binding to 
both 5-HT
1A
Rs and SERTs.
Figure 12. Chemical structures of 15 and 16.
Figure 13. Chemical structures of 17–20.
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Finally, the presence of a 3β-aminotropane moiety instead of the piperazine or piperidine ring 
is unfavorable for the development of High affinity 5-HT
1A
R ligands (Figure 14) [22].
5.2.3. Modification of the spacer
In LCPAs, the four-carbon alkyl chain seems to be the most favorable for high 5-HT
1A
R affinity. 
Indeed, its shortening reduces affinity, according to the rank order of potency C-4 > C-2 > C-3 [4].
However, the butyl chain can be substituted by a propylthio bridge, as confirmed by the high 
5-HT
1A
R affinity of compound 21 (Figure 15). The NH
2
 function is responsible for its selectiv-
ity over α
1
-ARs (5-HT
1A
R/α
1
-AR = 55) [15].
The oxybutynin chain of aripiprazole (7) is also favorable for high 5-HT
1A
R affinity. Besides 
its main use in the treatment of schizophrenia and bipolar disorder, 7 is also employed as 
an add-on treatment in major depressive disorder, tic disorders, and irritability associated 
with autism. In addition, its systemic or local administration induces antinociceptive effects. 
Unlike other atypical antipsychotics approved by FDA (e.g., clozapine, olanzapine, quetiap-
ine, ziprasidone, and risperidone), which are D
2
R antagonists, 7 behaves as a D
2
R and D
3
R 
partial agonist. Moreover, it shows partial agonism at 5-HT
1A
Rs and, similarly to the other 
atypical antipsychotics, is an antagonist at 5-HT
2A
Rs and 5-HT7Rs as well as a partial agonist 
at 5-HT2CRs [23].
The presence of a hydroxyl group in the butyl chain is well tolerated. BMY 14802 (22) (Figure 16), 
for example, is a 5-HT
1A
R agonist that also attenuates dyskinesia produced by L-DOPA.
A hydroxyalkyl chain also characterizes a series of molecules (23–26) (Figure 17), in which the 
combination of structural elements favoring the affinity for 5-HT
1A
Rs (heterocyclic nucleus, 
hydroxyalkyl chain, and 4-substituted piperazine) was used to obtain ligands with high 
Figure 14. General structure of 3β-aminotropane derivatives.
Figure 15. Chemical structure of 21.
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5-HT
1A
 affinity and selectivity over other 5-HT subtypes [24]. In particular, while compounds 
23–25 show an outstanding 5-HT
1A
R affinity, compound 26 is selective for 5-HT2CRs (pKi = 8.3).
In a series of compounds prepared to discover mixed 5-HT/dopamine receptor agents as novel 
antipsychotics, amide 27 (Figure 18) emerges for its high affinity for D
3
Rs, 5-HT
1A
Rs, and 
5-HT
2A
Rs. Its low affinity for D
2
Rs, 5-HT2CRs, and hERG channels reduces extrapyramidal side effects, risk of obesity under chronic treatment, and incidence of torsade des pointes, respectively 
[25]. The replacement of the ether/amide bridge with a sulfonamide function affords a series 
of quinoline or isoquinoline derivatives endowed with multireceptor 5-HT
1A
R/5-HT
2A
R/5-HT7R/
D
2
R/D
3
R profile and behaving as 5-HT
1A
R agonists, D
2
R partial agonists, and 5-HT
2A
R/5-HT7R 
antagonists (Figure 18). They produce significant antidepressant activity in mice [26]. In par-
ticular, 28 also displays remarkable antipsychotic effects in MK-801-induced hyperlocomotor 
activity in mice.
The inclusion of the alkyl chain of LCAPs in a cyclohexyl ring leads to more conformation-
ally constrained analogues (e.g., 29) (Figure 19) [15]. Trans derivatives show 5-HT
1A
R affinity 
significantly higher than that of their corresponding cis isomers (e.g., trans 29 and cis 29). 
The insertion of a hydroxyl substituent in the cyclohexyl moiety is also well tolerated (30). 
Interestingly, compared to flexible 4-carbon alkyl chain analogues, 1e,4e-disubstituted cyclo-
hexane derivatives maintain very high 5-HT
1A
R affinity, but in some cases, the functional 
profile is modulated from partial agonism to antagonism [27].
Figure 16. Chemical structure of BMY 14802 (22).
Figure 17. Chemical structures of 23–26.
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Figure 19. Chemical structures of 29 and 30.
The alkyl chain can be partially included in aromatic functions, including pyrrole (RWJ 25730, 31), 
phenyl (mazapertine, 32), or benzimidazole (33) (Figure 20) [15]. The multireceptor affinity of 32 
can be ascribed to its ability to adopt a variety of low-energy conformations. Indeed, constraining 
its 2-isopropoxyphenyl and piperazine moieties, affording compound 34, significantly reduces 
affinities for α
1
-ARs and D
2
Rs, but not that for 5-HT
1A
Rs.
The insertion of the 1,3-dioxolane nucleus in the chain is also well tolerated. Compound 35, for 
example, is a potent partial agonist and shows moderate selectivity over α
1
-ARs (Figure 21) [28]. 
Substitutions at C-8 position of the 1,4-dioxaspiro[4, 5]decane moiety reduce 5-HT
1A
R/α
1
-AR 
selectivity ratio because of the significant decrease of binding affinity and intrinsic activity for 
5-HT
1A
Rs with respect to α
1
-ARs. The isosteric replacement of one (oxathiolane derivative 36) 
and especially of two (dithiolane derivative 37) oxygen atoms with sulfur atoms proves to be 
tolerated (Figure 21). The replacement of the piperazine ring with a more flexible basic chain 
affords compound 38, which behaves as a potent and selective 5-HT
1A
R partial agonist endowed 
with neuroprotective activity in vitro and potent antinociceptive activity in an in vivo model 
[28]. A similar profile is shown by the unsubstituted analogue 39 characterized by good 5-HT
1A
/
α
1
-AR selectivity (Figure 21).
Similar structure-activity relationships (SARs) can be observed when the spiro-cyclohexyl ter-
minal fragment in both piperazine and open-chain series is replaced by a 2,2-diphenyl moiety.
Figure 18. Chemical structures of 27 and 28.
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The replacement of the 1,3-dioxolane nucleus with other pentatomic rings bearing H-bond 
acceptor groups (tetrahydrofuran or cyclopentanone) or an H-bond acceptor and donor 
group (cyclopentanol) (Figure 22) causes an overall reduction of affinity at α
1
-ARs, while 
both potency and efficacy are increased at 5-HT
1A
Rs.
5.2.4. Modification of the terminal fragment
The numerous structurally different terminal fragments, as already seen for ligands reported 
above, demonstrate that this moiety is less critical for 5-HT
1A
R interaction [8]. The dual SSRI 
and 5-HT
1A
R agonist vortioxetine (40), approved by FDA for the treatment of major depres-
sive disorders in adult in 2013, even lacks this function (Figure 23).
The replacement of the azaspirodecanedione moiety of 9 with an N-phthalimido group affords 
the nonselective ligand 41 (Figure 24) [15]. Shortening the length of its butyl chain to three 
or two units significantly decreases the affinity. The presence of an isosteric sulfonyl function 
instead of a carbonyl group of the phthalimide moiety, as in ipsapirone (42), is compatible with 
Figure 20. Chemical structures of 31–34.
Figure 21. Chemical structures of 35–39.
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Figure 22. Bioisosteric replacement of oxygen atoms of 5-HT
1A
R 1,3-dioxolane ligands.
Figure 23. Chemical structure of vortioxetine (40).
the maintenance of similar 5-HT
1A
R affinity and improved selectivity over α
1
-ARs (Figure 24) 
[15]. The replacement of the phthalimide moiety of 41 with an adamantyl amide group, lead-
ing to 43, also increases the selectivity for 5-HT
1A
Rs over α
1
-ARs (Figure 24) [15]. As in the 
case of the prototypical 5-HT
1A
R antagonist 12, substituents can be present at amidic NH [15]. 
The replacement of the pyridine ring of 12 with a pyrimidine substituent leads to the similarly 
potent 5-HT
1A
R antagonist 44. The isosteric inversion of the amide function and the presence of 
a phenyl group in the bridge, affording 45, are tolerated (Figure 24). Considering both affinity 
and selectivity for 5-HT
1A
Rs, among some 5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl deriva-
tives obtained by inserting an alkyl chain of variable length (preferably a three-membered alkyl 
chain) in the α, β, or ω position, the best derivatives are 46 and 47 (Figure 24) [15].
Several molecules, bearing an isonicotinic moiety as the terminal fragment of LCAPs, 
show nanomolar and subnanomolar affinities for 5-HT
1A
Rs, 5-HT
2A
Rs, and 5-HT2CRs and moderate or no affinity for other relevant receptors (D
1
Rs, D
2
Rs, α
1
- and α
2
-ARs) [29]. In 
particular, derivative 48, bearing a propyl chain as a spacer, shows the highest affinity 
for 5-HT
1A
Rs and selectivity over dopaminergic, adrenergic, and other serotoninergic 
receptors (Figure 25). LCAPs bearing a 1,2,3,4-tetrahydroisoquinoline-3-carboxamide in 
the terminal fragment can show affinity for 5-HT
1A
Rs and/or 5-HT7Rs [30]. Indeed, while compounds 49 and 50, with a methylthio substituent in the ortho-position show high 
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5-HT
1A
R affinity, the replacement of the phenyl ring in the arylpiperazine moiety with a 
benzisoxazole system, affording, for example, 51 and 52, significantly increases the affinity 
for 5-HT7R (pKi = 7.7 and 7.6, respectively) (Figure 25). The insertion of a spiro-cyclopen-tane or cyclohexane in position 3 of pyrrolidin-2,5-dione leads to a series of arylpipera-
zines, among which derivatives 53 and 54 with an ethylene spacer and a CF
3
 substituent in 
meta position of the phenyl ring show both anticonvulsant activity and high 5-HT
1A
R and 
5-HT
2A
R affinity (Figure 25) [31].
A β-tetralonohydantoin as terminal fragment characterizes a series of compounds, which 
show high 5-HT
1A
R affinity (pK
i
 = 7.3–8.2) combined with moderate to high 5-HT
2A
R affinity 
(pK
i
 = 6.7–7.3). Among them, compound 55 (Figure 26) is a postsynaptic 5-HT
1A
R antago-
nist and produces the characteristic effect of presynaptic 5-HT
1A
R agonists [32]. Moreover, 
it behaves as a 5-HT
2A
R antagonist. Due to its interesting 5-HT
1A
/5-HT
2A
 functional profile, 
55, tested for its potential psychotropic activity, shows diazepam-like anxiolytic activity and 
behaves as a weak antidepressant.
Among new LNCPs with structural modifications in the terminal fragment, in the alkyl chain 
length and in the substituents of the piperazine fragment, the 2-ethoxy quinazolinone deriv-
atives 56 and 57 are the most interesting ligands, showing high affinity for 5-HT
1A
Rs and 
5-HT7Rs (Figure 26) [33].
Figure 24. Chemical structures of 41–47.
4WD to Travel Inside the 5-HT1A Receptor World
http://dx.doi.org/10.5772/intechopen.69348
87
In a more recent work, the quinazolinone system has been replaced by 6-phenyl-4(3H)-pyrim-
idinone as a result of splitting bicyclic quinazolinone system [34]. The benzo-cracking strategy 
(compounds 58–62) causes a decrease in affinity for both receptors. In functional assays, these 
derivatives behave as weak 5-HT
1A
R and 5-HT7R antagonists (Figure 26).
1,2,4-Triazine-6(1H)-one derivatives also display dual affinity for 5-HT
1A
Rs and 5-HT7Rs. SAR studies have revealed that receptor affinity and selectivity depend on the nature of the sub-
stituent in position 3 of the triazinone fragment as well as on the substitution pattern of the 
phenylpiperazine moiety [35]. The best 5-HT
1A
R affinity values and selectivity over 5-HT7Rs are displayed by compounds 63 and 64 (Figure 26).
The 3,5-dioxo-(2H,4H)-1,2,4-triazine-tethered arylpiperazines have been identified as agonists 
with high affinity for 5-HT
1A
Rs. Several members of this series such as 65 show nanomo-
lar affinity for 5-HT
1A
Rs, high selectivity over α
1
-AR, and potent agonist activity (Figure 26) 
[36]. The 1,2,3-benzotriazin-4-one terminal fragment characterizes some 5-HT
1A
R antagonists 
prepared as potential antiproliferative agents in cancer cell lines [37]. These compounds are 
endowed with high 5-HT
1A
R affinity and moderate or no affinity for other receptors (5-HT
2A
Rs, 
5-HT2CRs, D1Rs, D2Rs, α1- and α2-ARs). In particular, derivative 66 shows picomolar affinity 
for 5-HT
1A
Rs (Figure 26).
MP 3022 (67), the lead compound of a large series of 4-alkyl-1-(o-methoxyphenyl)-pipera-
zines containing a benzotriazole terminal fragment, behaves as a potent pre- and postsyn-
aptic 5-HT
1A
R antagonist, but it is not selective for 5-HT
1A
Rs over α
1
-ARs (Figure 26) [15]. 
4-Benzoyl-1,2,3-triazole derivatives (e.g., 68), open-chain analogues of their benzotriazole bio-
isosteres, bind to 5-HT
1A
Rs in a nanomolar range and are highly selective over 5-HT
2A
Rs and 
5-HT2CRs (Figure 26) [15].
Purine 2,6-dione core has also been used as a terminal fragment to combine the 5-HT
1A
R activ-
ity with the phosphodiesterase (PDE) inhibition [38]. Both effects might be advantageous in 
Figure 25. Chemical structures of 48–54.
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the treatment of neuropsychiatric disorders. Among the compounds bearing this core, 69–72 
show high affinity for 5-HT
1A
Rs and, in the case of 69 and 70, also for 5-HT7R. At the same time, compounds 69–72 show a moderate to very low D
2
R affinity. From functional assays, 
69–71 behave as 5-HT
1A
R antagonists, whereas 72 is an agonist (Figure 27) [38, 39]. The anti-
depressant activity of 69 and 70 at a dose of 1.25 mg/kg is similar to that of citalopram given 
at the same dose [38]. The annulation of the purine system at 7,8-positions with an imidazole 
moiety affords ligands with a wide spectrum of activities (high 5-HT
1A
R or 5-HT7R affinity, 
Figure 26. Chemical structures of 55–68.
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Figure 27. Chemical structures of 69–73 and general structure of purine 2,4,8-trione derivatives.
mixed 5-HT
1A
R/5-HT7R affinity, and additional affinity for D2R) [40]. The tested compounds are in the ranges defined by the “rule of five” (logP < 5), which indicates good intestinal per-
meability and metabolic stability. In preliminary pharmacological in vivo studies, the selected 
compound 73 behaves as a potential antidepressant in mice and, at the dose of 2.5 mg/kg, 
shows anxiolytic effect (Figure 27). Finally, purine 2,4,8-trione derivatives show affinity val-
ues lower than those of the corresponding purine 2,4-dione analogues (Figure 27) [41].
5.2.5. Main interactions of arylpiperazines with 5-HT
1A
Rs
Two main interactions prove to be important for the affinity of arylpiperazines for 
5-HT
1A
Rs: (a) an ionic bond between the protonated nitrogen atom of the piperazine ring 
and the carboxyl oxygen of the side chain of Asp3.32 and (b) an edge-to-face CH-π interac-
tion between the aromatic ring and the Phe6.52 residue, which stabilizes the ligand bind-
ing. The basic pharmacophore of the 5-HT
1A
R is the same for agonists and antagonists and 
consists of an aromatic nucleus and a basic nitrogen atom, whose optimal distance is 5.2 Å, 
while the nitrogen lies at 0.2 Å above the plane defined by the reference ring (Figure 28) [4].
Due to the highly flexible linker (usually 2-4 methylene units), using different experimen-
tal and modeling techniques, various attempts have been conducted to determine the bioac-
tive conformation of LCAPs [42]. Assuming that active conformations of LCAPs are closely 
related to those in solutions or in solid state, two-dimensional (2D) NMR and crystallographic 
methods were often applied. The 2D NMR studies indicated that compounds with tetrameth-
ylene spacer can adopt extended, bent, or folded conformations. On the other hand, analysis 
of Cambridge Structural Database showed that linear geometries predominated. Molecular 
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modeling studies (conformational analysis, docking, dynamics), provided with structural 
investigations or conducted separately, also gave equivocal results suggesting the possibility 
of different bioactive conformations of LCAPs.
5.3. Aminotetralins
For a long time, 2-aminotetralin structure has been known to be pharmacologically impor-
tant. Initially, aminotetralins were characterized by their sympathomimetic action, i.e., the 
induction of mydriasis, contraction of the uterus, changes in blood pressure, and respiration, 
as well as increased intestinal motility in in vivo experiments. During the late 1960s, the dis-
covery of their activity at central dopamine receptor led to active synthesis programs all over 
the world. The 2-aminotetralin structure has proven to be a valuable scaffold not only for the 
development of 5-HTR ligands, but it also characterizes dopamine and adrenergic receptor 
ligands, as well as compounds interacting with melatonin receptors [15]. The main SARs of 
aminotetralins are summarized in Figure 29.
The position of the hydroxyl group in the aromatic ring of the tetralin scaffold is crucial to 
address ligands toward 5-HT or dopamine receptors. Indeed, 8-hydroxy-2-(N,N-di-n-pro-
pylamino)tetralin (8-OH-DPAT, 74) (Figure 30) is a very potent and selective 5-HT receptor 
ligand, while its 5- and 7-hydroxy regioisomers (5- and 7-OH-DPAT) are potent dopamine 
receptor ligands. [3H]8-OH-DPAT is frequently used to label 5-HT
1A
Rs. Both its enantiomers 
show high affinity for 5-HT
1A
Rs. However, in functional experiments, the (R) enantiomer 
behaves as a full agonist while its antipode as a partial agonist.
Compounds obtained by replacing the 8-hydroxy substituent with 8-methoxy (8-MeO-
DPAT, 75), 8-acetyl (76), and 8-methoxycarbonyl (77) or 8-carboxamide (78) groups are about 
as potent as the parent compound, indicating that the proton of the 8-hydroxy group is not 
essential for drug-receptor interaction (Figure 30). A carboxylic group in the same position 
(79) is not favorable. Aryl and heteroaryl groups, such as phenyl, fluorophenyl, methoxyphe-
nyl, acetylphenyl, 2-furyl, and benzylthio, are well tolerated. For most derivatives, the (R)-
enantiomers are more potent than the (S)-enantiomers. The introduction of a fluorine atom 
at position C-5 of 74, affording 80, slightly decreases 5-HT
1A
R affinity. In functional studies, 
the (R)-enantiomer behaves as a partial agonist, while the (S)-enantiomer is a pure antago-
nist at both pre- and postsynaptic receptors. An antagonist is also obtained by introducing a 
methyl group in 5-position of 74 (compound 81) (Figure 30). The replacement of the N,N-di-n-
propyl groups of 74 or 75 with smaller or larger di-n-alkyl substituents results in a significant 
Figure 28. General structure of LCAPs and pharmacophoric model of 5-HT
1A
R (Adapted with permission from Ref. [4]. 
Copyright (2014) American Chemical Society).
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decrease in affinity. The rank order of potency is N,N-dipropyl > N,N-diethyl > N,N-dibutyl > 
N,N-dimethyl group.
Compared to the N,N-dialkylated 8-MeO-DPAT (75), the monoalkylated N-propyl derivative 
84 shows slightly lower affinity, whereas the non-substituted 8-methoxy-2-aminotetralin (82) 
is almost inactive (Figure 30). The piperidine analogue 83 (Figure 30) is 16–29-fold less active 
than the N-mono (84) or N,N-dipropyl derivative (75). Compounds with high-affinity values 
are obtained if the amino group is monosubstituted with relatively large substituents as a 
phenylalkyl moiety, with the 3-phenylpropyl-8-methoxy group being optimal (85). Even an 
extra N-methyl group (86) or bulky substituents such as an N-(phthalimidobutyl) group are 
also well tolerated (87).
The incorporation of the nitrogen atom in the tetralin nucleus furnishes the series of 1,2,3,4-tet-
rahydroisoquinoline (THIQ) derivatives, which bind to 5-HT
1A
Rs and 5-HT
2A
Rs. SAR studies 
performed on the THIQ class lead to the synthesis of 1-adamantoyloaminoalkyl derivatives 
endowed with high affinity for 5-HT
1A
Rs (pK
i
 = 7.3–8.3) and behaving as postsynaptic 5-HT
1A
R 
partial agonists (Figure 31).
Ring contraction (indamines) or ring expansion (benzocycloheptamines) of the cycloexyl ring 
of 2-aminotetralins decreases 5-HT
1A
R affinity. The replacement of the tetralin scaffold with 
the chroman nucleus does not influence affinity and selectivity.
Figure 30. Chemical structures of 74–87.
Figure 29. Main SARs of aminotetralins.
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Among the four enantiomers obtained by the introduction of a methyl group in position 1 of 
75, only (S,R)-88 displays high affinity for 5-HT
1A
Rs (Figure 32). In functional tests, it behaves 
as a mixed partial 5-HT
1A
R agonist/D
2
R antagonist.
The restriction of the conformation of 88 by the incorporation of the C-1 methyl and the C-2 
nitrogen into an azetidine (89) or pyrrolidine (90) ring significantly enhances 5-HT
1A
R affin-
ity (Figure 32). These more rigid four/six and five/six fused angular tricyclic 2-aminotetralins 
are N-substituted with either n-propyl or its bioequivalent 2-propenyl group. The cis race-
mates of both series are more potent than cis-88. The hydroxy derivatives display selective 
5-HT
1A
R agonist activity, whereas the methoxy analogues show mixed 5-HT
1A
R agonist and 
dopamine antagonist activities. In general, the cis analogues are more potent than the corre-
sponding trans analogues, and in the cis series, the (S,R)-enantiomers display higher potency 
(Figure 32). Nitrogen substitution with either an n-propyl or an allyl group leads to ligands 
with similar activities, whereas their replacement with a bulky α-methylbenzyl group pro-
duces a decrease in activity. The incorporation of the C-1 methyl and the C-2 nitrogen into 
a more flexible six-membered piperidine ring (91) is less favorable for 5-HT
1A
R affinity. In 
contrast to the pyrrolidine series, in these six/six fused angular tricyclic 2-aminotetralins, the 
trans enantiomers are more potent than the cis antipodes (Figure 32).
The introduction of a methyl group in position 3 of 75 is not favorable for high 5-HT
1A
R affin-
ity. Consequently, the incorporation of the C-2 nitrogen and C-3 methyl into a five-membered 
Figure 31. General structure of THIQ derivatives.
Figure 32. Chemical structures of 88–91.
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pyrrolidine ring also leads to five/six fused linear tricyclic 2-aminotetralins, which are only 
moderately active.
A different six/six fused angular tricyclic of 2-aminotetralin is obtained by incorporating the 
8-oxygen atom and C-7 into a six-membered ring, obtaining 92 and 93, respectively. However, 
these modifications reduce affinity. The (R) configuration is more favorable than the (S) one 
(Figure 33).
A further decrease in affinity is shown by compounds bearing an annulated pyrrole ring in 
which the NH moiety is in the same position as the hydroxy group of 74. On the contrary, the 
annulation in which the indole NH is in C-7 of the tetralin nucleus affords potent 5-HT
1A
R 
ligands (94) (Figure 34).
The introduction of a formyl group at C-1 of 94, affording 95 (Figure 34), modulates the 
pharmacological profile from a mixed D
2
/5-HT
1A
R agonist to a selective 5-HT
1A
R agonist. 
The enantiomers of 95 are full agonists with affinities comparable to that of 74. Both affin-
ity and selectivity for 5-HT
1A
Rs are improved by the substitution at C-1 of the pyrrole 
ring with a cyano group. In fact, the enantiomers of the 1-cyano derivative 96 are almost 
equipotent to the corresponding formyl derivative 95, while 1-chloro (97) and 1-(1,1,1-tri-
fluoroethyl) (98) substituents lead to less potent derivatives. The substitution at the C-2 
of the pyrrole with a carboxamide (99) or cyano function (100) is also well tolerated, 
compound 100 being a potent 5-HT
1A
R agonist. In the C-1 and C-2 substituted series, the 
(R)-enantiomers display high and moderate affinity for 5-HT
1A
Rs and D
2
Rs, respectively. 
The (S)-enantiomers are somewhat less potent but even more selective 5-HT
1A
R ligands. 
An unsubstituted indole-NH moiety is crucial for the interaction with 5-HT
1A
Rs. Indeed, 
the N-methyl compounds are significantly less potent. Without loss in 5-HT
1A
R affinity, 
one of the propyl groups can be replaced by a variety of large substituents such as the glu-
tarimide-butyl one (101–103) (Figure 34). In functional tests, most of the (R)-enantiomers 
behave as full agonists, whereas the corresponding (S)-enantiomers are partial agonists.
5.4. Indolylalkylamines
The prototype of this class of compounds is the endogenous ligand 5-HT (Figure 1), which 
behaves as a potent 5-HT
1A
R agonist (pK
i
 = 8.4). The alkylation at α or β positions of trypt-
amine moiety, as well as the incorporation of its alkylamine side chain into a 4-substituted tet-
rahydropyridine ring, strongly decreases 5-HT
1A
R affinity [15]. The removal of the hydroxyl 
group at position C-5 also reduces 5-HT
1A
R affinity, the unsubstituted tryptamine analogue 
Figure 33. Chemical structures of 92 and 93.
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being 30-fold less potent than 5-HT. However, the 5-hydroxyl group can be replaced by a 
5-methoxy or 5-carboxamide function, leading to 5-MeOT (104) and 5-CT (105), respectively, 
which show high 5-HT
1A
R affinities (Figure 35).
The 4-substituted tetrahydropyridine analogue of 104 (RU 24969, 106) and the N,N-di-n-
propyl analogue of 105 (DP-5-CT, 107) also show high 5-HT
1A
R affinities and behave as potent 
and selective 5-HT
1A
R agonists (Figure 35). The incorporation of the side chain of 105 into a 
3-substituted tetrahydropyridine, affording 108, slightly decreases 5-HT
1A
R affinity, which is 
further reduced by the removal of the 5-carboxyamido function or its replacement with sub-
stituents such as a methoxy or cyano group. Linking the indolyl moiety to an N-substituted 
piperazine ring through a proper alkyl spacer (LCAPs) also proves to be compatible with high 
5-HT
1A
R affinity and selectivity [43]. In particular, hydroxy, methoxy, or carboxamide groups 
in position 5 of the indole moiety yield ligands with high 5-HT
1A
R affinity. Such ligands tol-
erate several substituents in the piperazine ring. Though the optimal linker to connect the 
indolyl moiety to the N-substituted piperazine is the n-butyl chain, an n-propyl spacer is also 
suitable, as demonstrated by the good 5-HT
1A
R affinity showed by compounds 109 and 110 
(Figure 36) [44].
A compound with an n-butyl chain is the potent and selective 5-HT
1A
R ligand 111 (Figure 36). 
Within this series of derivatives, the introduction of a residue in the para position of the phe-
nyl ring reduces dopaminergic activity and, consequently, improves 5-HT
1A
R selectivity [45].
The indolylalkylamine moiety is also present in multitarget compounds simultaneously act-
ing as SSRIs and 5-HT
1A
R antagonists and potentially useful for the treatment of depression. 
Among these, the benzoxazine derivative 112 shows high affinity for both 5-HT
1A
Rs and 
SERTs (pK
i
 SERT = 8.5), but no selectivity over α
1
-ARs. It behaves as a 5-HT
1A
R partial agonist 
[46]. On the contrary, the aryloxyalkylamine derivative 113 (pK
i
 SERT = 9.3) behaves as a full 
5-HT
1A
R antagonist (Figure 37) [47].
Figure 34. Chemical structures of 94–103.
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The hybridation between the chromane-based structure, present in 5-HT
1A
R antagonists, and 
the 3-indolyl-alkylamine moiety, embedded in numerous SSRIs, leads to compounds with 
mixed profiles. 5-Carboxamide-8-fluoro derivatives as well as 5-carboxamide-8-des-fluoro 
analogues with proper N-alkyl chains display good affinities for both 5-HT
1A
Rs and 5-HT 
reuptake site [48]. In particular, 114 (Figure 37) behaves as a very potent 5-HT
1A
R antagonist 
and SSRI. The constrained amide conformation inherent in the lactam group results in less 
potent 5-HT
1A
R antagonist activity [49]. Another LCAP, obtained by combining 3-indolyl-
alkylamine and arylpiperazine through a butyl chain (vilazodone, 115), proves to be suitable 
for the interaction with both SERTs and 5-HT
1A
Rs. Indeed 115, showing subnanomolar 5-HT 
reuptake inhibitor activity and subnanomolar 5-HT
1A
R affinity, behaves as a 5-HT
1A
R agonist 
high selective over other GPCRs [43]. 5-Substituted bis-3-propylindole derivatives connected 
to N1 and N4 atoms of the piperazine ring also bind both SERTs and 5-HT
1A
Rs, as suggested 
by compounds 116 and 117 (Figure 37), which show good affinities for both targets [50].
5.5. Ergolines
The tetracyclic ergoline skeleton is a common structural element contained in all ergot alka-
loids. Such compounds are used in the treatment of several pathophysiological conditions, 
because of their wide spectrum of central and peripheral pharmacological activities. They can 
be considered as rigid analogues of both indolylalkylamines and catecholamines. Therefore, 
it is not surprising that they are able to nonselectively bind to adrenergic, dopaminergic, 
and serotoninergic receptors. Potent and selective 5-HT
1A
R ligands have been developed by 
combining the structural elements of the indolylethylamines and the 2-aminotetralins into a 
Figure 36. Chemical structures of 109–111.
Figure 35. Chemical structures of 104–108.
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partial ergoline skeleton [15]. Among the compounds belonging to this series, LY228729 (118; 
Figure 38) displays the highest affinity for 5-HT
1A
Rs and good selectivity over a lot of other 
monoaminergic receptors. In functional assays, 118 behaves as a both pre- and postsynaptic 
5-HT
1A
R agonists.
Though several tetracyclic ergolines, such as LSD (119), lisuride (120), or pergolide (121), 
show high affinities for 5-HT
1A
Rs, they lack of selectivity over the other monoaminergic recep-
tors. The improvement of the selectivity for 5-HT
1A
Rs over 5-HT
2
Rs as well as D
1
Rs, D
2
Rs, and 
α-ARs can be obtained by introducing the bulky and metabolically stable tert-butyl group 
in the phenyl ring at C-13 of the ergoline skeleton. Some derivatives (122–124; Figure 38), 
bearing a heteroaryl substituent at C-9, display nM affinity for 5-HT
1A
Rs and at least 100-fold 
selectivity over the other tested receptors. In contrast, the presence of a tert-butyl group at 
C-14 favors the selectivity for 5-HT
2
R.
Among the 5(10→9)abeo-ergoline derivatives, compound 125 displays good 5-HT
1A
R affinity 
and selectivity over 5-HT
2
Rs, D
1
Rs, D
2
Rs, and α-ARs. In this class of compounds, 5-HT
1A
R 
affinity is enhanced by the conversion of the 8β-hydroxymethyl group into a methyl group. 
Indeed, the transformation of 125 into the deoxy derivative 126 leads to appreciable increase 
of 5-HT
1A
R affinity. An improvement of 5-HT
1A
R selectivity can be obtained by the reduction 
of the 2,3-double bond of 126, leading to the indolines 127 and 128 (Figure 39).
The stereochemistry at C-3 is very important for the 5-HT
1A
R profile. In particular, compound 128 
displays an outstanding selectivity for 5-HT
1A
Rs over 5-HT
2
Rs, D
1
Rs, D
2
Rs, and α
1
- and α
2
-ARs.
Figure 37. Chemical structures of 112–117.
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5.6. Aporphines
These compounds, whose prototype is (R)-apomorphine (129), have extensively been studied 
for their interaction with dopamine receptors in the CNS. In the effort to extend SAR stud-
ies of (R)-aporphines at dopamine receptors, (R)-(−)-10-methyl-11-hydroxyaporphine 130 
(Figure 40), the 10-methyl substituted derivative of 129, was surprisingly discovered [15] as 
a potent and selective 5-HT
1A
R agonist devoid of dopaminergic activity. The corresponding 
(S)-enantiomer behaves as an antagonist at postsynaptic 5-HT
1A
Rs and is tenfold less potent 
than its antipode. Changes in steric bulk and/or electronic properties of the C10-substituent 
as compared to a C10-methyl group produce a decrease in 5-HT
1A
R affinity. For example, the 
substitution of the methyl at C-10 with an ethyl group (131) reduces the 5-HT
1A
R affinity of 
about 20-fold. Compound 132, the N-desmethyl derivative of 130, shows about 7-fold lower 
than 5-HT
1A
R affinity (Figure 40). However, such a modification mostly reduces the affinities 
Figure 38. Chemical structures of 118–124.
Figure 39. Chemical structures of 125–128.
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for D
1
Rs (62-fold) and D
2
Rs (>9.3-fold) and, consequently, improves 5-HT
1A
R selectivity. The 
removal of the substituent at position C-10 is compatible with 5-HT
1A
R interaction. In par-
ticular, among the C-11-monosubstituted aporphines, ethyl (133) and phenyl (134) deriva-
tives show the highest affinities for 5-HT
1A
Rs and good selectivity over both D
1
Rs and D
2
Rs 
(Figure 40).
Rigidifying (R)-aporphines derivatives by linking C-1 and C-11 into a fused pentacyclic or 
hexacyclic ring strongly reduces 5-HT
1A
R affinity. However, among the compounds within 
this series, the imino derivative 135 displays poor selectivity for 5-HT
1A
Rs over both 5-HT7Rs and D
2
Rs, whereas the regioisomer 136 is selective for 5-HT7Rs.
5.7. Imidazolines
The observation that the beneficial properties of the α2C-AR agonists and α2A-AR antagonists ally-
phenyline (137) and cyclomethyline (138) on morphine dependence proved to be associated to a 
significant antidepressant effect led to the hypothesis that ligands bearing the 2-substituted imid-
azoline nucleus as a structural motif can also be suitable to interact with 5-HT
1A
Rs (Figure 41).
Experiments carried out in the presence of the 5-HT
1A
R antagonist WAY100135 confirmed 
that 5-HT
1A
R activation is involved in the observed antidepressant-like activity [51]. The 
investigation of a wide series of 2-substituted imidazolines linked to an aromatic moiety by 
Figure 40. Chemical structures of 129–136.
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a biatomic bridge highlighted that a polar function (-O- or –NH- group) and a methyl group 
in the bridge as well as the suitable chirality and a proper steric hindrance in the aromatic 
area favor 5-HT
1A
R recognition and activation. In particular, (S)-naphthaline (139) shows 
the highest 5-HT
1A
R affinity within the series (Figure 41). In mice it displays antidepressant-
like effect at a very low dose (0.01 mg/Kg) and proves to be more efficacious and potent than 
amitriptyline (15 mg/kg), a tricyclic antidepressant commonly used in human therapy [52].
5.8. 1,4-Dioxanes
The design and synthesis of 5-HT
1A
R ligands bearing the 1,4-dioxane nucleus were inspired 
by the observation that the potent α
1
-AR antagonist WB4101 (140) also shows high 5-HT
1A
R 
affinity [53]. In the effort to discriminate between 5-HT
1A
R and α
1
-ARs, the quite planar 
1,4-benzodioxane structure of 140 was replaced by the less conformationally constrained 
6-aryl-1,4-dioxane ring, maintaining the 2,6-dimethoxy substitution or removing one or both 
methoxy groups of the phenoxy terminal. The most interesting results are shown by the 
6,6-diphenyl substituted compounds 141–143, which display nanomolar 5-HT
1A
R affinities 
(Figure 42).
In particular, 143 behaves as a potent full 5-HT
1A
R agonist with a pD
2
 value significantly 
higher than those of the reference compounds 5-HT and 8-OH-DPAT. This derivative also 
shows a good selectivity for 5-HT
1A
Rs over α
1A
−, α1B−, and α1D−AR subtypes [54]. The ste-reogenic center in position 2 of the 1,4-dioxane nucleus appears to play a critical role in the 
Figure 41. Chemical structures of 137–139.
Figure 42. Chemical structures of 140–144.
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interaction with α
1
-AR and 5-HT
1A
 R systems, a reversal enantioselectivity governing the 
5-HT
1A
R or α
1
-AR recognition. Indeed, concerning 5-HT
1A
Rs, the optimal affinity resides in 
the 2-(S) configuration, which, on the contrary, is less favorable for the interaction with α
1
-
AR subtypes. This result is particularly interesting because, as the eutomers for 5-HT
1A
Rs 
behave as distomers for α
1
-AR, the 5-HT
1A
R/α
1
-AR selectivity ratio significantly increases 
compared to the corresponding racemate [55].
A good selectivity for 5-HT
1A
Rs over α
1
-ARs and dopamine D
2
-like receptors is also obtained by 
inserting a –OCH
2
OCH
3
 group in 2-position of the phenoxy terminal (compound 144; Figure 42). 
The pharmacological profile of 144 and docking studies suggest that 5-HT
1A
Rs also accommo-
date substituents bulkier than the methoxy group. Instead, both α
1
-ARs and D
2
-like receptors 
have more stringent steric requirements being intolerant to the increase of steric bulk itself. Due 
to its 5-HT
1A
R activation, 144 significantly reduces anxiety-linked behaviors in mice [56].
6. Conclusion
In summary, the currently main knowledges of the four-wheel drive (4WD: who, why, where, 
what, and drugs) vehicle by which to travel inside the 5-HT
1A
R world, have been presented. 
Such a travel, begun 30 years ago with the identification of 5-HT
1A
R coding gene, is far from 
the conclusion. Indeed, despite no X-ray structure is deposited to date, it is possible to answer 
quite exhaustively the question “who” this receptor is. However, the most intriguing question 
is “why” it continues to be a so attractive target several years after its identification. Several 
evidences are available about “where” 5-HT
1A
R is expressed throughout the body, at both cen-
tral and peripheral levels. Between presynaptic (auto- and heteroreceptors) and postsynaptic 
receptors, are there differences which could allow us to target them selectively? Wider and 
wider is the field of “what” effects this receptor can elicit under physiological and pathological 
conditions directly or through the modulation of several other receptor systems or the stimula-
tion of the secretion of various hormones. Well known is its involvement in anxiety, depression, 
epilepsy, mood disorders, learning, and memory. Consequently, growing is its importance 
in the treatment of such pathologies. Moreover, the interest for 5-HT
1A
R as an attractive tar-
get of drugs is increased by further physiologically governed functions, including feeding/
satiety, temperature regulation, sleep, pain perception, and sexual activity. The stimulation 
of 5-HT
1A
Rs has been demonstrated to activate several different biochemical pathways and 
signals through both G-protein-dependent and G-protein-independent pathways. However, 
it cannot be ruled out that underlying mechanisms are far from being completely understood, 
making more and more complex the net of pathways through which the primary impulses 
unwind themselves. Finally, the discovery of “drugs” able to selectively activate or inhibit 
5-HT
1A
R might help to better characterize such a receptor and the physiological functions in 
which it is involved. Despite the numerous published papers and synthesized and tested mol-
ecules, the results are not completely satisfactory yet. The reasons can be ascribed partly to the 
great similarity of the ligand recognition transmembrane region of 5-HT
1A
Rs with other mem-
bers of the family or other GPCRs, partly to bimodal effect of 5-HT
1A
R activation dependent on 
the neuroanatomical location of the receptors and the concentration of the ligand.
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